March 11, 2010 - Ablitech relocates to The Garden
March 8, 2010 - Ablitech Unveils Unique Gene Delivery System
March 5, 2010 - Enterprise Biomed Students Tour Ablitech Research Center
September 23, 2009 - Mississippi Technology Alliance President and CEO Dr. Randy Goldsmith today announced that the Mississippi Seed Fund invested $100,000 in Ablitech, Inc., of Hattiesburg.
"Ablitech's experienced management team and strong relationships with university researchers position the company for rapid growth", said Goldsmith. "This investment will help the company ramp up product development and the critical research needed to secure future contracts."
Ablitech was formed in 2006 to rapidly bring cutting-edge university knowledge in medicinal chemistry and polymer science to market for healing the human body. The company specializes in converting university research into practical prototypes that can be marketed to pharmaceutical and medical device companies. Ablitech will use the seed fund investment for product research and market development.
"Without the support of MTA and the Mississippi Seed Fund, Ablitech would have been forced to leave the state to obtain financing for its new product developments", said Ken Malone, CEO of Ablitech. "Now, we can develop our new cancer therapy, Versadel, right where the initial discoveries were made, in Mississippi."
The Mississippi Legislature established the Mississippi Seed Fund to provide high tech start-up companies with access to pre-seed financing, early stage risk capital and product development capital to stimulate and accelerate the development of high-performance, technology-based business ventures in Mississippi. The fund is managed by the Mississippi Technology Alliance. Recipients must have a cash match from accredited investors to obtain funding.
The Mississippi Technology Alliance is a non-profit organization with the mission to drive innovation and technology-based economic development for the State of Mississippi. For more information, visit www.technologyalliance.ms
Pictured (L to R): Lylla Joe (MTA), Nick Hammond,
Lisa Kemp, and Ken Malone of Ablitech.
October 16, 2008 - LifeFlow, Inc. heals arteries and restores their natural flow and flexibility.
Unlike other companies in the $3+ billion coronary stent market, LifeFlow's products are Biotransformable. By releasing healing drugs over several months and interacting with the artery to biotransform into a flexible micro mesh, LifeFlow's products overcome the shortfalls of incumbent metal stents and new biodegradable stents currently in clinical trials.
LifeFlow's Biotransfromable product has successfully completed initial animal testing. An investment of six million dollars is sought to accelerate development of the product into and through phase I clinical trials.
Product development to date has been funded by two Small Business Innovation Research (SBIR) grants from the National Science Foundation (NSF) and from seed investments. The NSF grant was due in part to "an impressive publication and patent record" * of the primary investigator and "the significant impact on the US market for coronary stents." *
The officers of LifeFlow have strong business operations and financial experience, a track record of successfully commercializing inventions and expertise in polymer science and medicinal chemistry.
LifeFlow has an exclusive license for coronary stents based on materials developed by Ablitech, Inc. (www.ablitech.com). The intellectual property was initially developed by the University of Southern Mississippi's world renowned Polymer Science and Engineering School.
* Quotes from the reviews of the funded SBIR proposal submitted by Ablitech to the NSF.
May 02, 2008 - Ablitech, Inc. of Hattiesburg, Mississippi has received $100,000 in funding from the National Science Foundation (NSF) through their Small Business Innovation Research (SBIR) program for the development of a new cancer treatment.
"This is very risky but very exciting research, and has the potential to be a game-changing cancer therapy." according to the NSF reviewers.
Ablitech's PolyRNA technology kills cancer cells without harming healthy cells in the body, thus avoiding the dangerous and painful side effects common in chemotherapy.
"PolyRNA is still in the early stages of development." according to Dr. Lisa Kemp, Ablitech's Chief Science Officer. "Funding from the prestigious National Science Foundation will help move this technology from the laboratory into patient treatment in a timely manner."
"PolyRNA is one of many radical new technologies for healing the human body which Ablitech is developing", said Dr. Nick Hammond, Ablitech's Chief Technology Officer.
April 21, 2008 - Polymer Science, Medical Technology Come Together at Ablitech
April 15, 2008 - Ablitech Wins Innovator Award
August 15, 2007 - Ablitech receives $100,000 grant from NSF
August 7, 2007 - Inventors' Research Transforms The Marketplace
December 4, 2006 - Ablitech Receives First Patent
May 20, 2006 - Ablitech Wins FedEx Business Plan Competition
April 4, 2006 - Ablitech Wins Business Plan Competition
